MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

Search

Grifols SA

Открыт

СекторФинансы

8.464 0.5

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

8.42

Макс.

8.564

Ключевые показатели

By Trading Economics

Доход

17M

69M

Продажи

183M

2B

P/E

Средняя по отрасли

36.313

20.525

Прибыль на акцию

0.101

Рентабельность продаж

3.491

Сотрудники

23,833

EBITDA

57M

482M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+65.92% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.6B

5.2B

Предыдущая цена открытия

7.96

Предыдущая цена закрытия

8.464

Техническая оценка

By Trading Central

Уверенность

Very Strong Bullish Evidence

Grifols SA График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

2 апр. 2025 г., 17:19 UTC

Приобретения, слияния, поглощения

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 апр. 2025 г., 13:02 UTC

Приобретения, слияния, поглощения

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 апр. 2025 г., 10:13 UTC

Приобретения, слияния, поглощения

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 июл. 2024 г., 10:40 UTC

Приобретения, слияния, поглощения

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 июл. 2024 г., 09:13 UTC

Приобретения, слияния, поглощения

Grifols Faces Delisting Bid From Founding Family and Brookfield

15 апр. 2025 г., 09:55 UTC

Обсуждения рынка

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2 апр. 2025 г., 09:27 UTC

Популярные акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Сравнение c конкурентами

Изменение цены

Grifols SA Прогноз

Целевая цена

By TipRanks

65.92% рост

Прогноз на 12 месяцев

Средняя 14.02 EUR  65.92%

Максимум 19.05 EUR

Минимум 11 EUR

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Grifols SA на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

3 ratings

2

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

8.006 / 8.544Поддержка и Сопротивление

Краткосрочная

Very Strong Bullish Evidence

Среднесрочная

Strong Bearish Evidence

Долгосрочная

Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.